CA-ROOTSTOCK-SOFTWARE
30.6.2020 07:02:07 CEST | Business Wire | Press release
Some partnerships are strengthened through difficult times. Rootstock Software and Mobidiag Ltd . found themselves in just this situation. Collaborating since 2018, the two companies have now been working toward respective missions around the COVID-19 pandemic. Mobidiag is a manufacturer of molecular diagnostic solutions for the detection of infectious diseases. Rootstock is a leading provider of Cloud ERP on the Salesforce Platform .
When the pandemic hit, Mobidiag quickly mobilized to develop and launch tests to detect COVID-19 infections. In April 2020, it was granted emergency use authorization for its COVID-19 diagnostic tests in Finland, Sweden and France. Now, in June, it has received CE-IVD markings for its two tests that enable rapid and reliable detection of COVID-19 infections:
- Novodiag™ COVID-19 for single, on-demand tests.
- Amplidiag™ COVID-19 for batch volume tests at large laboratories.
These two tests are complemented by an antibody test, Anti-SARS-CoV-2 Rapid Test , which Mobidiag distributes from its venture partner in China, Autobio Diagnostics.
All together these tests mean Mobidiag offers a comprehensive diagnostic solution for novel coronavirus infections for hospital and lab-based settings, and it comes at an opportune time, as the demand for COVID-19 diagnostic devices and tests is high around the world.
“Since April 2018, we have used Rootstock ERP along with Salesforce Sales Cloud and Service Cloud,” said Harri Vaihinen, Senior Business Solution Specialist at Mobidiag . “We worked with Rootstock to enable greater integration and automation of our key processes across sales, inventory and service for greater efficiency, synchronization and a full view of data across these departments. Since we had this ERP and integrated processes in place, we were able to use these tools to support our rapidly increasing sales, including COVID-19 tests.”
“During the pandemic, Rootstock’s mission has been to support manufacturers, distributors and supply chain organizations in continuing to deliver vital products around the world,” said Pat Garrehy , CEO of Rootstock Software . “It’s impressive to have seen the strides Mobidiag has made to get their COVID-19 tests to market in such an accelerated timeframe. The world needs COVID-19 testing, and it’s gratifying to play even a small role in supporting Mobidiag in their objective to detect COVID-19 infections and slow the spread of the virus.”
Salesforce, Sales Cloud and others are among the trademarks of salesforce.com, inc.
About Mobidiag
Mobidiag is a commercial stage, fast growing molecular diagnostics company whose fast, cost-effective, widely applicable and robust technology makes the power of molecular diagnostics available to address the spread of infectious diseases and antimicrobial resistance by rapid detection of pathogens and their potential resistance to antibiotics. Through its Amplidiag™ and Novodiag™ solutions, Mobidiag offers a comprehensive range of molecular diagnostic solutions for the detection of infectious diseases to laboratories of all sizes.
About Rootstock
Rootstock Software is a worldwide provider of cloud ERP designed for manufacturing, distribution, and supply chain organizations. Rootstock Cloud ERP is a flexible, modern, and digitally connected system that transforms companies to deliver a more personalized customer experience, efficiently scale operations, and out-service the competition.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200629005024/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 14:03:00 CEST | Press release
Full data presented at ESOC 2026 further strengthen the clinical evidence supporting TIGERTRIEVER™ 13 for the treatment of distal vessel occlusion stroke — a segment representing nearly half of all ischemic strokes Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L
2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 14:00:00 CEST | Press release
“Eat Where Locals Eat” Making authentic Japanese dining experiences accessible to global travelers through instant reservations at over 70,000 restaurants nationwide. Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 14:00:00 CEST | Press release
Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies
FIFA and Fanatics Expand Wide-Ranging Relationship to Include Historic Exclusive Collectibles Agreement (Trading Cards, Stickers and Trading Card Games)7.5.2026 13:00:00 CEST | Press release
Partnership includes FIFA tournaments and events from 2031Agreement encompasses both physical and digital collectibles, and for the first time brings the player jersey patch program to international footballPre-match press conferences for the FIFA World Cup Final to take place at Fanatics Fest on Friday, 17 July 2026 In a landmark agreement expanding their already successful wide-ranging commercial relationship, FIFA and Fanatics have signed a long-term, exclusive collectibles licensing deal that features trading cards, stickers, and trading card games. The agreement, which will begin in full in 2031, covers both physical and digital collectibles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507105628/en/ An example of the product innovations that will be brought to fans under this new partnership is the highly sought-after player jersey patch program, including debut patches, which will be inserted into football tradin
DEFINITIVE Trial Reaches Major Milestone: All Centres Approved and More Than 50% Recruitment Achieved7.5.2026 11:21:00 CEST | Press release
Poster presented at ESMO Breast Cancer 2026: Exploring health policy and real-world treatment strategies for early-stage HER2-positive breast cancer across Europe. The DEFINITIVE project, a landmark European Union-funded international phase III clinical trial evaluating the use of the HER2DX diagnostic assay to guide personalised treatment in early-stage HER2-positive breast cancer (BC), announces two major operational milestones at the ESMO Breast Cancer 2026 congress. Approvals have been obtained in the 7 participating countries, 33 clinicals sites are now open for patient recruitment. The trial has reached over 50% of its recruitment target, marking a pivotal moment on the path toward to transforming HER2-positive BC treatment. About the DEFINITIVE Project The DEFINITIVE project is a 5-year, prospective, open-label, randomised, two-arm phase III international clinical trial conducted across 44 centres in 7 European member states and associated countries. The trial aims to demonstrat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom